Business Context and Reporting Period
TriSalus Life Sciences, Inc. filed a Form 8-K dated September 1, 2023, under Item 7.01, Regulation FD. The filing states that the Company may use an investor slide presentation in discussions with investors, analysts, and others. The referenced presentation is Exhibit 99.1, dated September 2023.
Financial Metrics and Liquidity
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics. It is not a financial-results filing.
Material Changes Versus Prior Period
The filing does not report financial or operational changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide specific guidance, forecasts, management outlook, risk disclosures, contingencies, or unusual financial items. It furnishes the investor presentation under Regulation FD; the information in Item 7.01 and Exhibit 99.1 is stated not to be filed for purposes of Section 18 of the Exchange Act and not to be incorporated by reference into other filings.
Investor Verification Items
- Review Exhibit 99.1, the September 2023 investor presentation, for any operating metrics, forecasts, strategic updates, or other information not reproduced in the filing text.
- Verify whether any presentation statements constitute forward-looking information and review related assumptions and risk factors.
- Consult the Company’s periodic reports for revenue, profitability, cash flow, debt, liquidity, and capital structure information.
- Note that the Company’s common stock trades under TLSI and its warrants under TLSIW on the Nasdaq Global Market.